Hyderabad, Telangana, India, October 2025 — Srinivas Mallavarapu has joined Dr. Reddy’s Laboratories as Chief of Global Portfolio & Head of Business Development, North America, bringing over two decades of rich experience in the global pharmaceutical industry. In his new role, he will focus on expanding Dr. Reddy’s North American business, strengthening the company’s global portfolio, and driving strategic partnerships to advance innovation and sustainable growth.
Srinivas returns to Dr. Reddy’s after an impactful tenure at Cipla, where he served as Executive Vice President – Global Portfolio & Business Development. During his time at Cipla, he played a pivotal role in defining the company’s global product pipeline and steering cross-functional teams to deliver business growth across complex generics, specialty injectables, and high-barrier-to-entry products in the US and Canada.
Earlier in his career, Srinivas spent several years at Dr. Reddy’s Laboratories, where he served in leadership positions including Sr. Director – Strategic Portfolio & Business Development and Director – US Portfolio Management. His contributions were instrumental in driving product commercialization strategies, developing five-year pipeline roadmaps, and establishing partnerships that enhanced the company’s presence in key global markets.
He began his professional journey at Keane Software Solutions, where he honed his analytical and strategic skills—laying the foundation for a data-driven approach to portfolio management and business development. Over the years, Srinivas has built a strong reputation for his ability to combine deep market understanding with innovative thinking to unlock value across pharmaceutical markets.
In his new capacity, Srinivas will lead Dr. Reddy’s North American growth strategy, leveraging his experience to advance its integrated global portfolio and further strengthen its leadership in the generics and specialty segments.
About Dr. Reddy’s Laboratories
Founded in 1984, Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, driven by the purpose of “Good Health Can’t Wait.” The company provides access to affordable and innovative medicines through its comprehensive portfolio, which includes APIs, generics, branded generics, biosimilars, and OTC products.
Operating across major markets such as the USA, India, Russia & CIS, China, Brazil, and Europe, Dr. Reddy’s is an industry leader known for scientific innovation, global quality standards, and patient-centric solutions. With a strong commitment to sustainability, access, and affordability, the company continues to invest in future growth areas like novel molecules, digital therapeutics, and consumer healthcare, while maintaining a steadfast focus on ESG excellence.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
